Table 4.
Proportions of kidney transplant recipients with a markedly subtherapeutic or supratherapeutic tacrolimus trough concentration during the first week after kidney transplantation.
| Tacrolimus trough concentration | Total (n = 40) | CYP3A5 expressers | CYP3A5 non-expressers | P valuea | ||
|---|---|---|---|---|---|---|
| Placebo (n = 12) | Diltiazem (n = 11) | Placebo (n = 8) | Diltiazem (n = 9) | |||
| Day 1 post-transplantation | ||||||
| Lower than 5 ng/mL, n (%) | 6 (15.0) | 4 (33.3) | 0 (0) | 1 (12.5) | 1 (11.1) | 0.152 |
| Lower than the target range, n (%) | 12 (30.0) | 7 (58.3) | 1 (9.1) | 2 (25.0) | 2 (22.2) | 0.078 |
| Higher than 15 ng/mL, n (%) | 7 (17.5) | 0 (0) | 1 (9.1) | 3 (37.5) | 3 (33.3) | 0.053 |
| Day 3 post-transplantation | ||||||
| Lower than 5 ng/mL, n (%) | 5 (12.5) | 4 (33.3) | 1 (9.1) | 0 (0) | 0 (0) | 0.078 |
| Lower than the target range, n (%) | 10 (25.0) | 8 (66.7) | 2 (18.2)b | 0 (0)b | 0 (0)b | < 0.001 |
| Higher than 15 ng/mL, n (%) | 1 (2.5) | 0 (0) | 0 (0) | 1 (12.5) | 0 (0) | 0.200 |
| Day 5 post-transplantation | ||||||
| Lower than 5 ng/mL, n (%) | 4 (10.0) | 1 (8.3) | 1 (9.1) | 2 (25.0) | 0 (0) | 0.491 |
| Lower than the target range, n (%) | 18 (45.0) | 7 (58.3) | 7 (63.6) | 2 (25.0) | 2 (22.2) | 0.158 |
| Higher than 15 ng/mL, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | – |
| Day 7 post-transplantation | ||||||
| Lower than 5 ng/mL, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | – |
| Lower than the target range, n (%) | 12 (30.0) | 1 (8.3) | 6 (54.5) | 2 (25.0) | 3 (33.3) | 0.115 |
| Higher than 15 ng/mL, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | – |
aFisher’s exact test.
bP < 0.05 versus CYP3A5 expressers with placebo group (Bonferroni correction for multiple comparisons).